cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk's outperforms Ozempic in III trial CagriSema Reduces Blood Pressure in

But it demonstrates why lean mass and muscle function cannot be treated as the same outcome

Semaglutid steht neuerdings auch als Tablette zur oralen Therapie des T2D zur Verfgung

Exercise Movement is life

A new analysis finds that people taking GLP-1 medications were less likely to experience heart attacks, strokes, or die early compared with those given a placebo, with benefits lasting over several years

(2020) characterized the differential affinities in more structural detail

Kidney function declined more slowly overall, the risk of major cardiovascular events such as heart attack was 18% lower and the risk of death from any cause was 20% lower among people who were treated with semaglutide compared with those who received the placebo, the research found